Enveda Therapeutics received FDA IND clearance and initiated a phase I trial of ENV‑6946, a first‑in‑class oral small molecule intended to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. The company described ENV‑6946 as a novel oral candidate derived from its natural‑product discovery platform. The IND start moves Enveda from discovery into clinical testing, aiming to evaluate safety, tolerability, and preliminary pharmacology. The program expands the field of oral immunomodulators for IBD, where new mechanisms and improved tolerability remain high priorities.